Philip Austin

AgriMetis LLC operates a biotech company, which engages in the development of crop protection agents. It also offers natural products derived compounds to protect crops from weeds, fungal diseases, and insect pests. Its AgriMetis technology platform employs multidisciplinary and integrated scientific approach that allows access to areas of chemical space and production routes that are inaccessible to others. The company was founded by Philip Goelet, Simon Aspland and Brian Green in March 2014 and is headquartered in Lutherville, MD.

Vestaron Corp. develops and markets bioinsecticides derived from naturally occurring peptides. It offers the following brands: Spear-T for the treatment of thrips, Spear-P controls Colorado Potato beetle, and Spear-C protects crops from lepidopteran pests. The company was founded by Glenn F. King in 2005 and is headquartered in Durham, NC.

Enko Chem, Inc. operates as a biotechnology company. The company was founded by Jacqueline Heard and is headquartered in Boston, MA.

Zebiai Therapeutics, Inc. develops artificial intelligence to predict and optimize novel small molecule modulators for challenging drug targets. The company was founded by Richard Wagner and is headquartered in Chestnut Hill, MA.

Anterra Capital BV (Anterra Capital) is an independent private equity firm founded in 2013. The firm is headquartered in Amsterdam, Netherlands.

Rabo Private Equity (RPE) is the private equity arm of the Rabobank Group and is headquartered in Utrecht. RPE originated in 1972 following the merger of two separate Dutch cooperative banks, the Cooperatieve Centrale Raiffeisen-Boerenleenbank in Utrecht and the Cooperatieve Centrale Boerenleenbank in Eindhoven. The firm was formally established in 1998. RPE is based in Utrecht and operates through two separate entities, Rabo Participaties and Rabo Capital.

Atlas Venture LLP is the London office of the independent and partner-owned venture capital investment group Atlas Venture Inc., headquartered in Boston with additional offices in Paris and Munich, plus an administrative office in Amsterdam. The group originated in 1980 and focuses on high-technology financing, aiming for a transatlantic operations model. The London office was established in 1986. The group manages a range of venture capital funds.